BCAL Diagnostics Appoints new CEO
- Breast cancer screening and diagnostic company BCAL Diagnostics (BDX) names Dr John Hurrell as its new Chief Executive Officer
- The incoming CEO’s remuneration is set at $300,000 per annum, plus a short-term incentive of 30 per cent of total employment cost for 2022
- The company Executive Chair Jayne Shaw said the company was excited to appoint a candidate as experienced and suitably skilled as Dr Hurrell
- Dr Hurrell will commence in his new role on February 14, with his time divided between Australia and the US
- BDX shares last traded at 12.5 cents at 1:05 pm AEDT
